Literature DB >> 8759182

Accelerated bone loss in post-menopausal women with mild primary hyperparathyroidism.

A B Grey1, J P Stapleton, M C Evans, I R Reid.   

Abstract

OBJECTIVES: Osteopenia is regarded as an indication for parathyroidectomy in primary hyperparathyroidism. However, uncertainty exists as to the extent and degree of the skeletal effects in those with mild disease. We sought to determine whether mild primary hyperparathyroidism affects the rate of bone loss in postmenopausal women.
DESIGN: Prospective 2-year comparison of rates of bone loss throughout the skeleton in 17 post-menopausal women with untreated mild asymptomatic primary hyperparathyroidism, and 48 age-matched, eucalcaemic controls.
RESULTS: The women with primary hyperparathyroidism had a greater annual rate of loss of bone mineral density (BMD) of the total body (mean +/- SE, primary hyperparathyroidism -1.15 +/- 0.31%, controls -0.39 +/- 0.10%; P = 0.04) and its spine subregion (primary hyperparathyroidism -2.08 +/- 0.88%, controls 0.04 +/- 0.35%; P = 0.02). Lumbar spine BMD tended to decline in the primary hyperparathyroidism group (-0.35 +/- 0.33%) in contrast to the control group (+0.28 +/- 0.22%) (P = 0.10). There were no significant differences between the groups in rates of changes of BMD in the legs or the proximal femur. In the primary hyperparathyroidism group, the rate of total body bone loss in the eight women known at study entry to have had long-standing (> 5 years) primary hyperparathyroidism was -1.52 +/- 0.61%/year, similar to that of the whole group.
CONCLUSION: Primary hyperparathyroidism is associated with an increased rate of loss of total body bone mineral density in post-menopausal women. Prolonged disease duration is therefore likely to be associated with an increasing risk of osteopenia, such that skeletal surveillance and interventions designed to reduce bone loss should be considered.

Entities:  

Mesh:

Year:  1996        PMID: 8759182     DOI: 10.1046/j.1365-2265.1996.744565.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  13 in total

Review 1.  Primary hyperparathyroidism: pathophysiology and impact on bone.

Authors:  A Khan; J Bilezikian
Journal:  CMAJ       Date:  2000-07-25       Impact factor: 8.262

Review 2.  The immune system and bone.

Authors:  Roberto Pacifici
Journal:  Arch Biochem Biophys       Date:  2010-06-17       Impact factor: 4.013

3.  Inhibition of antigen presentation and T cell costimulation blocks PTH-induced bone loss.

Authors:  Brahmchetna Bedi; Jau-Yi Li; Francesco Grassi; Hesham Tawfeek; M Neale Weitzmann; Roberto Pacifici
Journal:  Ann N Y Acad Sci       Date:  2010-03       Impact factor: 5.691

4.  The effects of raloxifene on bone turnover markers and bone mineral density in women on maintenance hemodialysis.

Authors:  Osamu Saito; Takako Saito; Shinji Asakura; Taro Sugase; Chiharu Ito; Yasuhiro Ando; Shigeaki Muto; Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2010-11-11       Impact factor: 2.801

Review 5.  Comparative efficacy of parathyroidectomy and active surveillance in patients with mild primary hyperparathyroidism: a systematic review and meta-analysis.

Authors:  N Singh Ospina; S Maraka; R Rodriguez-Gutierrez; A E Espinosa de Ycaza; S Jasim; M Gionfriddo; A Castaneda-Guarderas; J P Brito; A Al Nofal; P Erwin; R Wermers; V Montori
Journal:  Osteoporos Int       Date:  2016-08-25       Impact factor: 4.507

6.  Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss.

Authors:  Hesham Tawfeek; Brahmchetna Bedi; Jau-Yi Li; Jonathan Adams; Tatsuya Kobayashi; M Neale Weitzmann; Henry M Kronenberg; Roberto Pacifici
Journal:  PLoS One       Date:  2010-08-20       Impact factor: 3.240

7.  T cells potentiate PTH-induced cortical bone loss through CD40L signaling.

Authors:  Yuhao Gao; Xiaojun Wu; Masakazu Terauchi; Jau-Yi Li; Francesco Grassi; Sarah Galley; Xiaoying Yang; M Neale Weitzmann; Roberto Pacifici
Journal:  Cell Metab       Date:  2008-08       Impact factor: 27.287

8.  Regulatory T cells are expanded by Teriparatide treatment in humans and mediate intermittent PTH-induced bone anabolism in mice.

Authors:  Mingcan Yu; Patrizia D'Amelio; Abdul Malik Tyagi; Chiara Vaccaro; Jau-Yi Li; Emory Hsu; Ilaria Buondonno; Francesca Sassi; Jonathan Adams; M Neale Weitzmann; Richard DiPaolo; Roberto Pacifici
Journal:  EMBO Rep       Date:  2017-11-20       Impact factor: 8.807

Review 9.  T cells, osteoblasts, and osteocytes: interacting lineages key for the bone anabolic and catabolic activities of parathyroid hormone.

Authors:  Roberto Pacifici
Journal:  Ann N Y Acad Sci       Date:  2015-12-10       Impact factor: 5.691

10.  T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling.

Authors:  Masakazu Terauchi; Jau-Yi Li; Brahmchetna Bedi; Ki-Hyun Baek; Hesham Tawfeek; Sarah Galley; Linda Gilbert; Mark S Nanes; Majd Zayzafoon; Robert Guldberg; David L Lamar; Meredith A Singer; Timothy F Lane; Henry M Kronenberg; M Neale Weitzmann; Roberto Pacifici
Journal:  Cell Metab       Date:  2009-09       Impact factor: 27.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.